The Ledger

UnitedHealth Group just sold a piece of the exact business that wrecked its earnings last year to a private equity firm, and Wall Street cannot decide if that is reassuring or alarming. Bloomberg reported the evening of September 8, 2026 that UnitedHealth sold TPG, the Fort Worth-based alternative asset manager, an interest in part of Optum Health’s WellMed primary care clinic network in Florida, the value-based care business whose cost overruns drove much of UnitedHealth’s difficult 2025 and the leadership shakeup that followed. Terms were not disclosed. At the Wells Fargo 21st Annual Healthcare Conference on September 9, UnitedHealthcare Chief Financial Officer Wayne DeVeydt confirmed the arrangement, saying “we didn’t need the dollars, we have the dollars to invest, but we needed the focus and somebody that could actually work with us locally,” and framed it as a way to accelerate Florida clinic growth, currently about 15 new locations a year, without diverting management attention from the broader Optum Health turnaround; DeVeydt said Optum Health’s operating margin is tracking to roughly 2 percent in 2026, with internal targets of about 4 percent in 2027 and 6 percent in 2028. UnitedHealth shares fell 3 percent around the disclosure, with some investors reading a private equity partner buying into the specific clinics tied to last year’s problems as a signal management still is not ready to run that business alone; TPG separately bought a stake in Optum’s UK business earlier this year, a deal UnitedHealth has said generated 400 million dollars for the UnitedHealth Foundation. Confidence: Medium-High on the deal facts, drawn from Bloomberg’s reporting and DeVeydt’s own conference remarks as relayed by trade press; Low on the causal read of the stock reaction, drawn from secondary commentary rather than UnitedHealth’s own statement. Sources: UnitedHealth Sells Interest in Florida WellMed Clinics to TPG, Bloomberg, UnitedHealth Slips 3% as TPG Buys Into Florida WellMed Clinics Ahead of Guidance Reaffirmation, 24/7 Wall St., TPG takes stake in UnitedHealth’s Florida WellMed clinics, Private Equity Wire.

Two insurers left the same investor conference this week with opposite stock reactions, and the split was not about Medicare Advantage for once. Elevance Health Chief Financial Officer Marc Kaye told the Wells Fargo conference on September 10, 2026 that third-quarter adjusted earnings are tracking ahead of the company’s prior outlook, citing favorable benefit-expense performance across Medicare Advantage, Medicaid and the individual Affordable Care Act market, even as employer-group costs stay elevated; Elevance reaffirmed full-year 2026 adjusted earnings guidance of at least 27.00 dollars a share and said management now expects 2026 to be the trough year for Medicaid margins, with at least 12 percent adjusted earnings-per-share growth built into its 2027 baseline. Elevance shares rose roughly 5 percent on the update, a sharper reaction than UnitedHealth’s 3 percent decline the same week described above, even though both companies were affirming rather than cutting guidance, a reminder that at this point in the cycle investors are pricing insurers on the credibility of their turnaround story as much as the numbers themselves. Confidence: Medium-High on the guidance figures, drawn from Elevance’s own conference remarks as reported by trade press; Medium on the stock-move comparison, drawn from a single secondary analysis rather than this run’s own market data review. Sources: Elevance Health at Wells Fargo conference: growth plan stays on track, Investing.com, Elevance Health Inc at Wells Fargo Healthcare Conference Transcript, GuruFocus, Elevance Surges 5% on Strong Q3 Signal as UnitedHealth Falls 3%, Options Trading Report.

UPDATE: the Oklahoma hospital system that dodged one bond default deadline six days ago just missed the next one, and this time the rating agency called it exactly what it is. S&P Global Ratings downgraded Norman Regional Health System to D, its lowest possible rating, after the system failed to make a 7.1 million dollar principal and 4.9 million dollar interest payment due September 1, 2026, on top of $247.45 million in outstanding revenue bonds; the bond documents carry no formal grace period, making the missed payment a technical default rather than a warning sign. Bondholders agreed to postpone the payment until a new $40 million senior revenue bond issue, to be purchased by the system’s majority bondholders and given priority over the existing debt, closes; that closing was expected by September 15, 2026, alongside amended covenants and additional collateral pledged against real and personal property. This is the same interim-financing plan this run covered September 6 when S&P still rated the system CC, one notch above default; the plan held, but not fast enough to avoid the technical default S&P had flagged as a possibility when it placed the rating on CreditWatch August 31. Confidence: High. This run reviewed S&P’s own rating action as summarized directly by Bond Buyer. Sources: S&P downgrades Oklahoma health system’s rating to D after payment delay, Bond Buyer, Norman Regional Health System, OK Bond Rating Low, S&P Global Ratings.

A healthcare data company’s board just cleared a legal obstacle to selling itself, days after a private equity firm’s opening bid sent its stock up 13 percent. Definitive Healthcare Corp. disclosed in a September 9, 2026 filing that holders of its tax receivable agreement, including funds tied to Advent International, Spectrum Equity, 22C Capital and founder Jason Krantz, waived their right to an early-termination payment if the company signs a merger agreement by December 31, 2026, removing a cost that could have complicated a deal. The waiver follows Advent International’s non-binding proposal, disclosed September 1, 2026, to take Definitive Healthcare private for 1.02 dollars per share in cash, a 36 percent premium to the company’s 60-day volume-weighted average price of 0.75 dollars; a special committee of independent directors, advised by Rothschild & Co and Skadden Arps, is evaluating the offer and has said no decision has been made and no transaction is assured. Definitive Healthcare’s platform is used by pharmaceutical and health system customers to analyze provider and claims data, putting it in the same healthcare-data consolidation wave this run flagged September 9 with the Accumulus Technologies and Defacto Health acquisitions. Confidence: High on the filing and proposal facts, drawn from the company’s own disclosures. Sources: Special Committee of Definitive Healthcare Board Confirms Receipt of Going-Private Proposal from Advent International, Definitive Healthcare Investor Relations, Definitive Healthcare Corp., Form 8-K, SEC EDGAR, Definitive Healthcare Shares Rise 13% After Advent International Submits $1.02-Per-Share Proposal, Yahoo Finance.

200 million dollars: that is what a nerve-repair device maker paid to add the first sutureless technology of its kind to its product line, before a single competitor can catch up. Axogen announced September 10, 2026 that it entered a definitive agreement to acquire BioCircuit Technologies for 200 million dollars in cash, with 1 million dollars of that withheld pending post-closing purchase-price adjustments. The deal brings Axogen NerveTape, which received US Food and Drug Administration (FDA) clearance in July 2022 as the first sutureless device for peripheral nerve repair, broadening Axogen’s product portfolio beyond its existing nerve-graft and nerve-connector lines; Axogen said the acquisition should be accretive to revenue growth, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) margin and adjusted earnings per share in its first year, while the company stays free-cash-flow positive. The transaction, expected to close in the fourth quarter of 2026 pending customary conditions including the spinout of BioCircuit’s separate electronics research and development business, is paired with a 208.7 million dollar public stock offering Axogen announced the same day to help fund the purchase. Confidence: High. This run reviewed Axogen’s own announcement directly. Sources: Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies, GlobeNewswire, Axogen deepens nerve repair portfolio through $200m BioCircuit takeover, Medical Device Network.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Optum Health’s WellMed clinics (Florida interest)	TPG	Value-based primary care	Undisclosed; disclosed September 8, 2026	Bloomberg
BioCircuit Technologies	Axogen	Medtech, peripheral nerve repair	$200 million cash; announced September 10, 2026	GlobeNewswire
Norman Regional Health System (Series 2026 senior revenue bonds)	Majority existing bondholders	Distressed hospital debt refinancing	$40 million interim financing; expected to close by September 15, 2026	Bond Buyer
Definitive Healthcare Corp.	Advent International (non-binding proposal)	Healthcare data and analytics	$1.02 per share cash (36% premium); TRA waiver filed September 9, 2026 clears path to a signed deal by December 31, 2026	Definitive Healthcare Investor Relations

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent orders in the last 24 to 48 hours; the MultiPlan/Claritev out-of-network repricing multidistrict litigation (MDL 3121) remains in discovery with no ruling since its August 22 case management conference. A frontier check on the nonprofit hospital municipal bond market, a Ledger branch not touched in the last three issues, surfaced today’s Norman Regional default covered above as the sharpest live example of the credit stress that market has been pricing all year. An open-ended scan surfaced no additional transaction beyond the items covered above.